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Abstract
Introduction: To determine whether the PTPN22 (protein tyrosine phosphatase nonreceptor 22)/CSK (c-src tyrosine
kinase) pathway is implicated in the susceptibility and clinical heterogeneity of Henoch-Schönlein purpura (HSP) in
the largest series of Caucasian HSP patients ever assessed for genetic studies.
Methods: A set of 329 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and
the Michel et al. classification criteria and 515 sex and ethnically matched controls were recruited in this study. Two
well-known CSK (CSK rs34933034 and CSK rs1378942) and two functional PTPN22 (PTPN22 rs2476601 (R620W) and
PTPN22 rs33996649 (R263Q)) polymorphisms, previously associated with autoimmunity, were genotyped with
TaqMan single nucleotide polymorphism (SNP) genotyping assays.
Results: No significant differences in the genotype and allele frequencies between HSP patients and controls were
observed when the CSK rs34933034, CSK rs1378942, PTPN22 rs2476601 (R620W) and PTPN22 rs33996649 (R263Q)
polymorphisms were analyzed independently. In keeping with this observation, no significant differences were
found when we assessed these polymorphisms combined conforming haplotypes. In addition, there were no
differences in the allele or genotype frequencies when HSP patients were stratified according the age at disease
onset, sex, presence of arthralgia/arthritis, nephritis or gastrointestinal manifestations.
Conclusions: Our results do not support association between PTPN22/CSK and HSP.
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Introduction
Henoch-Schönlein purpura (HSP), also called immuno-
globulin A (IgA) vasculitis, is a leukocytoclastic vasculitis
characterized by IgA-dominant immune deposits involving
mainly the skin as well as other tissues [1]. HSP is more
common in children but is not exceptional in adults [1].
The main feature of this vasculitis is a palpable purpura in-
volving predominantly the lower extremities. Besides skin
involvement, HSP often causes joint pain and gastrointes-
tinal complications [2]. Nevertheless, renal manifestations
constitute the most serious complications of HSP [2] and
long-term morbidity and mortality in these patients are
mainly due to renal involvement. Although the molecular
bases underlying the origin of HSP have not been eluci-
dated yet, environmental and socioeconomical factors are
suggested to be involved in the disease pathogenesis [3].
Moreover, the relevance of genetic variants in both sus-
ceptibility and HSP clinical heterogeneity has been
demonstrated [3–5].
Protein tyrosine phosphatases (PTPs) are critical regulators
of T cell signal transduction [6]. Among these molecules, the
lymphoid-specific phosphatase (Lyp) is a 110-kDa PTP
encoded by the gene PTPN22 (protein tyrosine phosphatase
nonreceptor 22). Lyp is expressed in lymphocytes where it
physically associates to the SH3 domain of CSK (c-src tyro-
sine kinase) [6]. Since this binding has been considered as
the most powerful inhibitor of T cell activation, the
PTPN22/CSK pathway has been proposed as a master
regulator of autoimmunity [7] being a molecular pathway
shared by several inflammatory pathologies. In accordance
with that, some studies have described an association be-
tween two well-known genetic variants located in the CSK
gene (CSK rs34933034 and CSK rs1378942) and several
immune-mediated disorders such as systemic lupus ery-
thematosus and systemic sclerosis in Caucasian patients
[8, 9]. Additionally, a relationship between two functional
genetic variants located in the PTPN22 gene (PTPN22
rs2476601 (R620W) and PTPN22 rs33996649 (R263Q))
and some inflammatory diseases (such as type I diabetes,
systemic lupus erythematosus and rheumatoid arthritis)
has been demonstrated in Caucasians [6, 10, 11]. In line
with that, although the genetic influence of PTPN22/
CSK in several vasculitides (such as giant cell arteritis,
Behçet’s disease and antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitides [12–14]) has been dem-
onstrated, there is scarce information on the role of
PTPN22/CSK in HSP. In this regard, only a small cohort
of Caucasian patients was assessed to establish the poten-
tial implication of the PTPN22 rs2476601 (R620W) gen-
etic variant in HSP [15].
Taking these considerations together, this study aimed
at investigating whether the PTPN22/CSK pathway is
actually involved in both HSP susceptibility and clinical
heterogeneity. For this purpose, we analyzed two well-
known CSK (CSK rs34933034 and CSK rs1378942) and
two functional PTPN22 (PTPN22 rs2476601 (R620W) and
PTPN22 rs33996649 (R263Q)) polymorphisms, previously
associated with autoimmunity, in the largest series of
Caucasian patients with this vasculitis ever assessed for
genetic studies.
Methods
Patients and study protocol
A set of 329 Spanish patients with cutaneous vasculitis
who fulfilled Michel et al. [16] classification criteria for HSP
were included in the present study. According to them,
they were classified as having HSP if they fulfilled three or
more of the following characteristics: palpable purpura,
bowel angina, gastrointestinal bleeding, macroscopic or
microscopic hematuria, age at disease onset ≤20 years, and
no previous history of medications prior to the onset of the
disease. Typically, HSP is more common in children.
Although less common, HSP may also occur in adults
(in individuals older than 20 years). Therefore, the de-
velopment of this vasculitis in an adult was not an ex-
clusion criterion for the diagnosis of HSP. However,
adults presenting with palpable purpura required the
presence of other manifestations (other criteria proposed
by Michel et al.) and, of course, the exclusion of other vas-
culitis such as ANCA-associated vasculitis was required in
these cases. Also, all patients included in this series were
required to fulfill the American College of Rheumatology
classification criteria for HSP [17].
This collaborative study started 5 years ago. Because of
that, the median duration of follow-up of the patients
was 1.5 years. Nevertheless, some patients who had suf-
fered this vasculitis before and who still attended outpa-
tients clinics were retrospectively recruited.
Blood samples were obtained from patients recruited
from Hospital Universitario Lucus Augusti (Lugo), Hospital
Universitario Marqués de Valdecilla (Santander), Hospital
Universitario La Princesa (Madrid), Hospital Universi-
tario San Cecilio (Granada), Hospital Universitario Virgen
del Rocío (Sevilla) and Hospital Universitario de Basurto
(Bilbao). Information on the main clinical features of the
whole series of 329 HSP Spanish patients recruited in this
study is shown in Table 1. Joint manifestations were de-
fined if arthralgia or peripheral arthritis was observed
on examination. For gastrointestinal (GI) manifestations,
bowel angina was considered present if there was diffuse
abdominal pain that worsened after meals or bowel is-
chemia usually with bloody diarrhea. GI bleeding was
defined as the presence of melena, hematochezia, or a
positive test for occult blood in the stool. Renal mani-
festations were defined to be present if at least one of
the following findings was observed: hematuria (≥5 red
blood cells/hpf ), proteinuria (>300 mg/24 h), nephrotic
syndrome (1 g/day/m2 body surface area or >3.5 g/day
López-Mejías et al. Arthritis Research & Therapy  (2015) 17:286 Page 2 of 8
proteinuria with plasma albumin <25 g/l, with or with-
out edema) and nephritic syndrome (i.e., hematuria with
at least two of the following: hypertension, raised plasma
urea or creatinine, and oliguria). Renal and severe GI
manifestations were frequently observed in 34.6 % and
52.9 % of these patients.
A set of 515, sex and ethnically matched controls
(median [interquartile range (IQR)]: 48 [27–62] years;
51 % males and 49 % females) without history of cutaneous
vasculitis or any other autoimmune disease constituted by
blood donors from National DNA Bank Repository
(Salamanca, Spain), was also included in the study.
A subject’s written consent was obtained according to the
declaration of Helsinki, and the study was approved by the
Ethics Committees of Galicia for Hospital Universitario
Lucus Augusti, of Cantabria for Hospital Universitario
Marqués de Valdecilla, of Madrid for Hospital Universitario
La Princesa, of Andalucía for Hospital Universitario San
Cecilio and Hospital Universitario Virgen del Rocío, and of
País Vasco for Hospital Universitario de Basurto.
Genotyping
Genomic deoxyribonucleic acid (DNA) was extracted
from peripheral blood mononuclear cells using standard
methods. The selection of the single nucleotide polymor-
phisms (SNPs) was based on their previous association
with several inflammatory diseases and some types of
vasculitis. In this regard, two well-known SNPs located
within CSK, CSK rs34933034 (C__60143137_10) and CSK
rs1378942 (C___1642446_10), and two functional SNPs
located within PTPN22, PTPN22 rs2476601 (R620W)
(C__16021387_20) and PTPN22 rs33996649 (R263Q)
(C__25937239_30), were genotyped using TaqMan SNP
genotyping assays in a 7900 HT real-time polymerase
chain reaction (PCR) system, according to the condi-
tions recommended by the manufacturer (Applied Bio-
systems, Foster City, CA, USA). PCR was carried out in
a total reaction volume of 4 μl with the following amp-
lification protocol: denaturation at 95 °C for 10 min,
followed by 45 cycles of denaturation at 92 °C for 15 s
and then annealing and extension at 60 °C for 1 min.
Negative controls and duplicate samples were included
to check the accuracy of genotyping.
Statistical analysis
All genotype data were checked for deviation from Hardy-
Weinberg equilibrium (HWE) using http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl [18]. Statistical power for the study was calcu-
lated using CaTS – the power calculator for two-stage
association studies (http://www.sph.umich.edu/csg/abe-
casis/CaTS/) [19].
First, comparisons were performed considering all SNPs
independently. Both allelic and genotypic frequencies were
calculated and compared by χ2 or Fisher tests when neces-
sary (expected values below 5). Strength of association
was estimated using odds ratios (OR) and 95 % confidence
intervals (CI). Allelic ORs for CSK and PTPN22 poly-
morphisms were estimated using the major allele as a
reference. Genotype ORs for CSK polymorphisms were
estimated in three models: (1) using the GG genotype
as reference for CSK rs34933034, which was compared
with each other genotype (i.e.: GA vs. GG and AA vs. GG)
and the AA genotype as reference for CSK rs1378942,
which was compared with each other genotype (i.e.: AC
vs. AA and CC vs. AA); (2) the dominant model: AA +
GA vs. GG (reference) for CSK rs34933034 and CC +AC
vs. AA (reference) for CSK rs1378942; (3) the recessive
model: AA vs. GG+GA (reference) for CSK rs34933034
and CC vs. AA+AC (reference) for CSK rs1378942.
Subsequently, allelic combinations (haplotypes) of both
CSK and PTPN22 polymorphisms were performed in
order to uncover hidden signals in the PTPN22/CSK path-
way. Haplotypes were constructed using Haploview v4.2
software; haplotypic frequencies were compared by χ2 test
and the strength of association was estimated by OR
(using the major haplotype as a reference) and 95 % CI.
All analyses were performed with STATA statistical
software 12/SE (Stata Corp., College Station, TX, USA).
Results
Differences in genotype and allele frequencies between
HSP patients and controls
The CSK rs34933034, CSK rs1378942, PTPN22 rs2476601
(R620W) and PTPN22 rs33996649 (R263Q) genotypes
distribution were in Hardy-Weinberg equilibrium (Table 2)
and for these four SNPs the genotyping success in HSP
Table 1 Main clinical features of a series of 329 Spanish
patients with HSP
Main characteristics % (n/N)
Children (age ≤20 years)/adults (age >20 years) 267/62
Male/female 168/161
Age at the onset of the disease (years, median [IQR]) 7 [5–18]
Duration of follow-up (years, median [IQR]) 1.5 [1–4]
Palpable purpura and/or maculopapular rash 100 (329/329)
Joint manifestations (arthralgia and/or arthritis) 55.6 (183/329)
Gastrointestinal manifestations (if “a” and/or “b”) 52.9 (174/329)
a) Bowel angina 51.4 (169/329)
b) Gastrointestinal bleeding 15.5 (51/329)
Renal manifestations (if any of the following
characteristics)
34.6 (114/329)
a) Hematuria 33.7 (111/329)
b) Proteinuria 32.2 (106/329)
c) Nephrotic syndrome 3.0 (10/329)
d) Nephritic syndrome 1.2 (4/329)
HSP Henoch-Schönlein purpura, IQR interquartile range
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patients and controls was greater than 98 %. Accordingly,
less than 2 % of the samples failed the genotyping
process and were removed from our study. This study
had >80 % of power to detect genotypic OR >1.4 for
CSK rs34933034, CSK rs1378942, PTPN22 rs2476601
(R620W) and PTPN22 rs33996649 (R263Q).
Table 2 describes the distribution of CSK rs34933034,
CSK rs1378942, PTPN22 rs2476601 (R620W) and PTPN22
rs33996649 (R263Q) (considering these genetic variants in-
dependently) in HSP patients and controls. As shown in
Table 2, no significant differences in the genotype and allele
frequencies of these four SNPs between HSP patients and
controls were observed (p >0.10 in all the cases). Addition-
ally, no statistically significant differences were found when
we analyzed CSK polymorphisms under different genetic
models such as codominant, dominant and recessive
(Table S1 in Additional file 1). However, due the rela-
tively low number of PTPN22 mutant homozygous,
these genetic models could not be calculated for PTPN22
polymorphisms.
In a further step, we assessed CSK rs34933034 and
CSK rs1378942 combined conforming haplotypes. How-
ever, the haplotype analysis did not yield additional infor-
mation, as no differences between HSP patients and
controls were found (Table S2 in Additional file 2). It was
also the case when the analysis of PTPN22 rs2476601
(R620W) and PTPN22 rs33996649 (R263Q) combined con-
forming haplotypes was performed (Table S2 in Additional
file 2).
Differences in genotype and allele frequencies between
HSP patients according to the age at disease onset
Since HSP is generally a benign and self-limited path-
ology in children and a more severe condition in adults
[2], in our study we also assessed if potential differences
in CSK rs34933034, CSK rs1378942, PTPN22 rs2476601
(R620W) and PTPN22 rs33996649 (R263Q) could exist
in HSP patients stratified according to the age at dis-
ease onset. However, as shown in Table 3A and B, no
differences in genotype and allele frequencies were de-
tected between HSP in children (age ≤20 years) and adults
(age >20 years).
Differences in genotype and allele frequencies between
HSP patients according to the presence of nephritis and
gastrointestinal manifestations
The allele and genotype frequencies were also examined
in HSP patients stratified by the presence of nephritis.
Nevertheless, no statistically significant differences between
HSP patients with or without renal manifestations were
observed (Table 3A and B). This was also the case when
HSP patients with severe GI complications (GI bleeding or
bowel angina) were compared with those without these
complications (Table 3A and B).
Differences in genotype and allele frequencies between
HSP patients according to sex and the presence of joint
manifestations (arthralgia or arthritis)
Finally, we assessed if potential differences in genotype
and allele frequencies could exist in HSP patients strati-
fied according to sex and the presence of arthralgia or
arthritis. However, no statistically significant differences
in the genotype and allele frequencies were found be-
tween HSP patients stratified according to sex (Table S3
in Additional file 3). It was also the case when HSP pa-
tients were stratified according to the presence or absence
of joint manifestations (Table S3 in Additional file 3).
Discussion
Accumulating evidences clearly suggest that a common
genetic component may underlie different autoimmune
diseases. PTPN22/CSK pathway has been postulated as a
Table 2 Genotype and allele frequencies of CSK and PTPN22 gene polymorphisms in HSP patients and controls
Change Genotype, n (%) Allele test
SNP Locus 1/2 Sample set N 1/1 1/2 2/2 p OR [95 % CI]a
rs34933034 CSK G/A HSP patients 329 219 (66.6) 96 (29.2) 14 (4.3) 0.96 1.00 [0.77-1.28]
Controlsb 515 337 (65.4) 161 (31.3) 17 (3.3)
rs1378942 CSK A/C HSP patients 329 111 (33.7) 170 (51.7) 48 (14.6) 0.22 1.13 [0.93-1.38]
Controlsc 515 193 (37.5) 258 (50.1) 64 (12.4)
rs2476601 PTPN22 G/A HSP patients 329 285 (86.6) 42 (12.8) 2 (0.6) 0.16 1.34 [0.89-1.99]
Controlsd 515 462 (89.7) 51 (9.9) 2 (0.4)
rs33996649 PTPN22 C/T HSP patients 329 314 (95.4) 15 (4.6) 0 0.15 0.67 [0.36-1.22]
Controlse 515 480 (93.2) 34 (6.6) 1 (0.2)
HSP Henoch-Schönlein purpura, SNP single nucleotide polymorphism, N number of patients, OR [95 % CI] odds ratio with 95 % confidence interval
aFor the minor allele
bpHardy-Weinberg equilibrium = 0.67
cpHardy-Weinberg equilibrium = 0.12
dpHardy-Weinberg equilibrium = 0.64
epHardy-Weinberg equilibrium = 0.63
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Table 3 Genotype and allele frequencies of CSK and PTPN22 gene polymorphisms in HSP patients according to the age at disease onset and the presence/absence of renal and
GI manifestations
A. CSK polymorphisms
SNP Children (Age ≤20 years) HSP with renal manifestationsa HSP with GI manifestationsb
Yes (n = 267) No (n = 62) p OR [95 % CI] Yes (n = 114) No (n = 215) p OR [95 % CI] Yes (n = 174) No (n = 155) p OR [95 % CI]
CSK rs34933034
Genotypes
GG 172 (64.4) 39 (62.9) - Ref. 73 (64.0) 138 (64.2) - Ref. 122 (70.1) 97 (62.6) - Ref.
GA 83 (31.1) 21 (33.9) 0.72 0.90 [0.48-1.71] 37 (32.4) 65 (30.2) 0.77 1.08 [0.64-1.81] 47 (27.0) 49 (31.6) 0.27 0.76 [0.46-1.27]
AA 12 (4.5) 2 (3.2) 0.69 1.36 [0.28-12.9] 4 (3.5) 12 (5.6) 0.43 0.63 [0.14-2.18) 5 (2.9) 9 (5.8) 0.15 0.44 [0.11-1.53]
Alleles
G 427 (80.0) 99 (79.8) - Ref. 183 (80.2) 341 (79.3) - Ref. 291 (83.6) 243 (78.4) - Ref.
A 107 (20.0) 25 (20.2) 0.98 0.99 [0.60-1.69] 45 (19.7) 89 (20.7) 0.77 0.94 [0.62-1.43] 57 (16.4) 67 (21.6) 0.09 0.71 [0.47-1.07]
CSK rs1378942
Genotypes
AA 95 (35.6) 18 (29.0) - Ref. 44 (38.6) 69 (32.1) - Ref. 64 (36.8) 47 (30.3) - Ref.
AC 138 (51.7) 32 (51.6) 0.53 0.82 [0.41-1.60] 58 (50.9) 112 (52.1) 0.41 0.81 [0.48-1.37] 89 (51.1) 81 (52.3) 0.38 0.81 [0.48-1.34]
CC 34 (12.7) 12 (19.4) 0.14 0.54 [0.22-1.36] 12 (10.5) 34 (15.8) 0.12 0.55 [0.24-1.24] 21 (12.1) 27 (17.4) 0.11 0.57 [0.27-1.20]
Alleles
A 328 (61.4) 68 (54.8) - Ref. 146 (64.0) 250 (58.1) - Ref. 217 (62.4) 175 (56.5) - Ref.
C 206 (38.6) 56 (45.2) 0.18 0.76 [0.50-1.16] 82 (36.0) 180 (41.9) 0.14 0.78 [0.55-1.10] 131 (37.6) 135 (43.5) 0.12 0.78 [0.57-1.08]
B. PTPN22 polymorphisms
SNP Children (Age ≤20 years) HSP with renal manifestationsa HSP with GI manifestationsb
Yes (n = 267) No (n = 62) p OR [95 % CI] Yes (n = 114) No (n = 215) p OR [95 % CI] Yes (n = 174) No (n = 155) p OR [95 % CI]
PTPN22 rs2476601
Genotypes
GG 229 (85.8) 56 (90.3) - Ref. 99 (86.8) 186 (86.5) - Ref. 152 (87.4) 133 (85.8) - Ref.
GA 37 (13.9) 5 (8.1) 0.23 1.81 [0.67-6.16] 15 (13.2) 26 (12.1) 0.82 1.08 [0.51-2.24] 22 (12.6) 20 (12.9) 0.91 0.96 [0.48-1.95]
AA 1 (0.4) 1 (1.6) 0.28 0.24 [0.003-19.5] 0 3 (1.4) - - 0 2 (1.3) - -
Alleles
G 495 (92.7) 117 (94.4) - Ref. 213 (93.4) 398 (92.6) - Ref. 326 (93.7) 286 (92.3) - Ref.


















CC 256 (95.9) 58 (93.5) - Ref. 108 (94.7) 206 (95.8) - Ref. 165 (94.8) 149 (96.1) - Ref.
CT 11 (4.1) 4 (6.5) 0.43 0.62 [0.18-2.78] 6 (5.3) 9 (4.2) 0.66 1.27 [0.36-4.12] 9 (5.2) 6 (3.9) 0.57 1.35 [0.42-4.74]
TT 0 0 - - 0 0 - - 0 0 - -
Alleles
C 523 (97.9) 120 (96.8) - Ref. 222 (97.4) 421 (97.9) - Ref. 339 (97.4) 304 (98.1) - Ref.
T 11 (2.1) 4 (3.2) 0.43 0.63 [0.18-2.77] 6 (2.6) 9 (2.1) 0.66 1.26 [0.37-4.03] 9 (2.6) 6 (1.9) 0.58 1.35 [0.42-4.65]
HSP Henoch-Schönlein purpura, GI gastrointestinal, SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval
aIf any of the following characteristics: hematuria, proteinuria, nephrotic syndrome and/or nephritic syndrome














potential common genetic factor shared for different
autoimmune disorders [6, 8–11].
The vasculitides constitute a heterogeneous group of
diseases that often have overlapping clinical and patho-
logical manifestations [20]. Although their complex eti-
ology is far from being completely understood, genetic
factors appear to influence the development and progres-
sion of these conditions [3–5]. In this regard, an implica-
tion of PTPN22/CSK in the susceptibility to giant cell
arteritis, Behçet’s disease and ANCA-associated vasculit-
ides has been described in Caucasians [12–14]. However,
the potential influence of PTPN22/CSK in HSP remains
unclear. With respect to this, a few years ago Orozco et al.
did not observe a significant association between the
PTPN22 gene polymorphism and HSP [15]. This study
was based on the analysis of a single functional poly-
morphism (PTPN22 rs2476601 (R620W)) and it was
performed in a small cohort of only 57 HSP patients
[15]. Accordingly, a potential false negative result could
not be excluded due to the underpowered sample size
of the study. Because of that, in an attempt to establish
if PTPN22/CSK is actually involved in HSP, we analyzed
two well-known CSK and two functional PTPN22 poly-
morphisms, previously associated with autoimmunity,
in the largest series of Caucasian patients with this vas-
culitis ever assessed for genetic studies. Our results do
not show an implication of PTPN22/CSK polymorphisms
in the susceptibility to HSP.
The PTPN22/CSK pathway acts as an inhibitor of T
cell signaling [6]. T cells appear to be more relevant than
B cells in some autoimmune diseases whereas in others
it seems to be the opposite. With respect to this, the
relevance of IgA-dominant immune deposits in HSP de-
velopment suggests that the implication of T cells in
HSP may be less important than in other autoimmune
diseases or other types of vasculitis such as, for example,
in giant cell arteritis [1]. In this regard, the lack of asso-
ciation between PTPN22/CSK and susceptibility and clin-
ical spectrum of HSP found in our study supports the
hypothesis that B cells are more important than T cells in
HSP.
In keeping with our findings, no association with
PTPN22/CSK was also described in other immune-
mediated diseases such as multiple sclerosis and anky-
losing spondylitis [21, 22]. Taken together, the results
in terms of PTPN22/CSK association with autoimmune
diseases support the notion that different pathogenic
mechanisms are involved in the development of polygenic
disorders.
The results derived from the present study may be of
potential clinical interest. In this respect, since small mol-
ecule inhibitors of Lyp would have preventative and/or
therapeutic efficacy in patients with a wide range of auto-
immune diseases (especially in individuals who are carriers
of the PTPN22 rs2476601 (R620W) genetic variant), the
lack of association between the PTPN22/CSK polymor-
phisms pathway and HSP indicate that small molecule
inhibitors of Lyp may not have a beneficial effect in pa-
tients with this vasculitis.
To conclude, although our cohort of HSP patients
constitutes the largest series of Caucasian patients with
this vasculitis ever assessed for genetic studies, further
large collaborative studies in other populations are needed
to fully establish the role of T cell activation polymor-
phisms in HSP.
Conclusions
Our results do not support an association between
PTPN22/CSK gene polymorphisms and HSP. Consequently,
small molecule inhibitors of Lyp may not have a beneficial
effect in patients with HSP.
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